GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Therapeutic Solutions International Inc (OTCPK:TSOI) » Definitions » Beneish M-Score

Therapeutic Solutions International (Therapeutic Solutions International) Beneish M-Score : -4.35 (As of May. 13, 2024)


View and export this data going back to 2008. Start your Free Trial

What is Therapeutic Solutions International Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -4.35 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Therapeutic Solutions International's Beneish M-Score or its related term are showing as below:

TSOI' s Beneish M-Score Range Over the Past 10 Years
Min: -102.93   Med: -13.35   Max: -3.86
Current: -4.35

During the past 13 years, the highest Beneish M-Score of Therapeutic Solutions International was -3.86. The lowest was -102.93. And the median was -13.35.


Therapeutic Solutions International Beneish M-Score Historical Data

The historical data trend for Therapeutic Solutions International's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Therapeutic Solutions International Beneish M-Score Chart

Therapeutic Solutions International Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.30 -13.40 -4.55 -3.86 -4.35

Therapeutic Solutions International Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.86 -6.59 -5.37 -2.85 -4.35

Competitive Comparison of Therapeutic Solutions International's Beneish M-Score

For the Biotechnology subindustry, Therapeutic Solutions International's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Therapeutic Solutions International's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Therapeutic Solutions International's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Therapeutic Solutions International's Beneish M-Score falls into.



Therapeutic Solutions International Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Therapeutic Solutions International for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.5968+0.528 * 0.967+0.404 * 0.9834+0.892 * 0.476+0.115 * 1.2099
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.5994+4.679 * -0.395504-0.327 * 0.9918
=-4.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $0.02 Mil.
Revenue was 0.024 + 0.026 + 0.026 + 0.023 = $0.10 Mil.
Gross Profit was 0.013 + 0.019 + 0.016 + 0.015 = $0.06 Mil.
Total Current Assets was $0.09 Mil.
Total Assets was $3.29 Mil.
Property, Plant and Equipment(Net PPE) was $0.50 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.31 Mil.
Selling, General, & Admin. Expense(SGA) was $1.49 Mil.
Total Current Liabilities was $1.90 Mil.
Long-Term Debt & Capital Lease Obligation was $0.11 Mil.
Net Income was -0.427 + -0.602 + -0.562 + -0.578 = $-2.17 Mil.
Non Operating Income was 0.174 + -0.062 + 0.102 + -0.026 = $0.19 Mil.
Cash Flow from Operations was -0.206 + -0.311 + -0.337 + -0.201 = $-1.06 Mil.
Total Receivables was $0.03 Mil.
Revenue was 0.009 + 0.075 + 0.039 + 0.085 = $0.21 Mil.
Gross Profit was -0.037 + 0.066 + 0.03 + 0.069 = $0.13 Mil.
Total Current Assets was $0.31 Mil.
Total Assets was $3.61 Mil.
Property, Plant and Equipment(Net PPE) was $0.28 Mil.
Depreciation, Depletion and Amortization(DDA) was $0.25 Mil.
Selling, General, & Admin. Expense(SGA) was $1.96 Mil.
Total Current Liabilities was $2.21 Mil.
Long-Term Debt & Capital Lease Obligation was $0.01 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.019 / 0.099) / (0.025 / 0.208)
=0.191919 / 0.120192
=1.5968

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.128 / 0.208) / (0.063 / 0.099)
=0.615385 / 0.636364
=0.967

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (0.086 + 0.5) / 3.292) / (1 - (0.31 + 0.282) / 3.606)
=0.821993 / 0.835829
=0.9834

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=0.099 / 0.208
=0.476

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0.245 / (0.245 + 0.282)) / (0.312 / (0.312 + 0.5))
=0.464896 / 0.384236
=1.2099

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1.489 / 0.099) / (1.956 / 0.208)
=15.040404 / 9.403846
=1.5994

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.111 + 1.9) / 3.292) / ((0.011 + 2.21) / 3.606)
=0.610875 / 0.615918
=0.9918

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-2.169 - 0.188 - -1.055) / 3.292
=-0.395504

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Therapeutic Solutions International has a M-score of -4.35 suggests that the company is unlikely to be a manipulator.


Therapeutic Solutions International Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Therapeutic Solutions International's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Therapeutic Solutions International (Therapeutic Solutions International) Business Description

Traded in Other Exchanges
N/A
Address
701 Wild Rose Lane, Elk City, ID, USA, 83525
Therapeutic Solutions International Inc focuses on immune modulation for the treatment of several specific diseases. It is engaged in developing a range of immune-modulatory agents to target certain cancers, improve maternal and fetal health, fight periodontal disease, and for daily health. The business divisions of the company are Nutraceutical Division which produces nutraceuticals. Its current product, QuadraMune, is a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone. Cellular Division obtained exclusive rights to a patented adult stem cell for the development of therapeutics in the area of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and Lung Pathology (LP).
Executives
Thomas Ichim director 211 E. OSBORN RD, PHOENIX AZ 85012
Gerry B Berg officer: CFO 1658 AVENIDA LA POSTA, ENCINITAS CA 92024
Timothy G Dixon director, officer: Chairman, President, CEO 4093 OCEANSIDE BLVD., SUITE B, OCEANSIDE CA 92056
Barry Glassman officer: VP, Training & Education 2051 ELBOW LANE, ALLENTOWN PA 18103
James P Boyd director, 10 percent owner PO BOX 2145, RANCHO SANTA FE CA 92067

Therapeutic Solutions International (Therapeutic Solutions International) Headlines

From GuruFocus